Produção Nacional
Revisado por pares
Enriching cancer pharmacology with drugs of marine origin
2019; Wiley; Volume: 177; Issue: 1 Linguagem: Inglês
10.1111/bph.14876
ISSN1476-5381
AutoresPaula C. Jimenez, Diego Veras Wilke, Paola Cristina Branco, Anelize Bauermeister, Paula Rezende‐Teixeira, Susana P. Gaudêncio, Letícia V. Costa‐Lotufo,
Tópico(s)Synthesis and Biological Activity
ResumoMarine natural products have proven, over the last half‐century, to be effective biological modulators. These molecules have revealed new targets for cancer therapy as well as dissimilar modes of action within typical classes of drugs. In this scenario, innovation from marine‐based pharmaceuticals has helped advance cancer chemotherapy in many aspects, as most of these are designated as first‐in‐class drugs. Here, by examining the path from discovery to development of clinically approved drugs of marine origin for cancer treatment—cytarabine (Cytosar‐U®), trabectedin (Yondelis®), eribulin (Halaven®), brentuximab vedotin (Adcetris®), and plitidepsin (Aplidin®)— together with those in late clinical trial phases—lurbinectedin, plinabulin, marizomib, and plocabulin—the present review offers a critical analysis of the contributions given by these new compounds to cancer pharmacotherapy.
Referência(s)